Join Now

Author Archives: Press Release

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

Posted in BioUtah News | Tagged | Comments Off on iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

Altitude Lab Demo Day

As part of BioHive week, Altitude Lab hosted its annual Demo Day.

Posted in BioUtah News | Tagged | Comments Off on Altitude Lab Demo Day

Steve Pacelli Appointed CEO of Epitel, Inc.

Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth

Posted in BioUtah News | Tagged | Comments Off on Steve Pacelli Appointed CEO of Epitel, Inc.

Sera Prognostics Announces Pricing of $50 Million Public Offering

Sera Prognostics Announces Pricing of $50 Million Public Offering

Posted in BioUtah News | Tagged | Comments Off on Sera Prognostics Announces Pricing of $50 Million Public Offering

The Teva Turnaround: Steering a Company Comeback

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.

Posted in BioUtah News | Tagged | Comments Off on The Teva Turnaround: Steering a Company Comeback

Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

Posted in BioUtah News | Tagged | Comments Off on Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

Posted in BioUtah News | Tagged | Comments Off on bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology

EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology

Posted in BioUtah News | Tagged | Comments Off on EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Posted in BioUtah News | Tagged | Comments Off on Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening

Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening

Posted in BioUtah News | Tagged | Comments Off on Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Posted in BioUtah News | Tagged | Comments Off on Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Dr. Robert Langer and Brigadier General Larry Lunt Join Forces with Sethera

World-Renowned Scientist and Co-founder of Moderna, Dr. Robert Langer, to Guide Sethera’s Scientific Strategy; Brigadier General Larry V. Lunt, USAF (Ret.), Adds Decades of Strategic Leadership Experience to Sethera’s Board

Posted in BioUtah News | Tagged | Comments Off on Dr. Robert Langer and Brigadier General Larry Lunt Join Forces with Sethera